Clarient Launches New Colorectal Cancer Test
2008年7月1日 - 8:00PM
PRニュース・ワイアー (英語)
KRAS Test Identifies Mutation that Signals a Patient's Potential
Response to Specific Drug Therapies ALISO VIEJO, Calif., July 1
/PRNewswire-FirstCall/ -- Clarient, Inc. (NASDAQ:CLRT), a premier
anatomic pathology and molecular testing services resource for
pathologists, oncologists, and the pharmaceutical industry, today
announced its new offering, KRAS, which has been validated as a
laboratory-developed test to be used as a predictive molecular
biomarker for patients with colorectal cancer (CRC). The importance
of KRAS testing was recently reported at this year's ASCO meeting
in Chicago and is supported by data published in the Journal of
Clinical Oncology (JCO) in April 2008. Ron Andrews, Clarient's
Chief Executive Officer said, "Identifying the KRAS mutation can
help individual patients and their physicians understand the best
way to manage their disease, assisting them in selecting the most
appropriate therapy. There are more than 150,000 patients diagnosed
with colorectal cancer each year, many of whom must decide whether
anti-EGFR treatments will be used to manage their disease." In
colorectal cancers, EGF-receptors transmit a series of signals
through a complex path of intracellular proteins. These signals
ultimately instruct the cancer cell to undergo a transcription
process leading to cancer progression. Anti-EGF-receptor therapies
such as panitumumab (Vectibix(TM), Amgen) and cetuximab
(Erbitux(TM), ImClone Systems) work by blocking the activation of
EGF-receptor. By blocking activation of the receptor, these drugs
are successful in inhibiting downstream events that lead to
malignant signaling. KRAS is located downstream of EGF-receptor and
is a vital component in orchestrating this signaling process. It is
now understood that mutations in the KRAS gene impact the protein
function such that its signaling process is always turned "on,"
regardless of whether the EGFR has been activated or
therapeutically inhibited. Mutations in the KRAS genes have been
detected in about 40 percent of metastatic colorectal cancer
patients. "The recently published data set further validates the
importance of identifying molecular markers to help predict
therapeutic responses in individual patients. These discoveries are
a major step forward in advancing the field of personalized cancer
care," said Ken Bloom, M.D., Chief Medical Officer at Clarient.
"The high frequency of this mutation along with the clinical
utility of this assay suggests that it has the potential of being
applied to virtually all colon cancer cases." Bloom continued,
"Furthermore, our ability and approach at Clarient -- to understand
key oncogenic pathways and how they interact as therapies are
applied to patients -- will allow us to develop additional tests
for a range of cancer indications." Andrews added, "This and other
upcoming biomarker introductions illustrate how science and the
Clarient business model work in harmony. The accuracy of gene tests
like KRAS is improved when only the cancer cells of interest are
chosen for analysis. Clarient is the only lab in the industry that
allows community-based pathologists to select the cells of interest
via our internet-based virtual microscopy solution, insuring that
the most accurate KRAS results are obtained. KRAS is an outstanding
addition to our extensive test menu. We are proud to be a leader in
offering the latest in cancer diagnostic testing, allowing patients
to avoid unnecessary toxicities, treatment delays, and higher
overall cost of therapy." About Clarient Clarient combines
innovative technologies with world class expertise to assess and
characterize cancer. Clarient's mission is to provide the services,
resources and critical information to improve the quality and
reduce the cost of patient care as well as accelerating the drug
development process. The Company's principal customers include
pathologists, oncologists, hospitals and biopharmaceutical
companies. The rise of individualized medicine as the new direction
in oncology has created the need for a centralized resource
providing leading diagnostic technologies such as flow cytometry
and molecular testing. Clarient is that resource, having created a
state-of-the-art commercial cancer laboratory providing the most
advanced oncology testing and drug development services available
both onsite and over the web. Clarient is a Safeguard Scientifics,
Inc. partner company. http://www.clarientinc.com/ About Safeguard
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc.
(NYSE:SFE) provides growth capital for entrepreneurial and
innovative technology and life sciences companies. Safeguard
targets technology companies in Software as a Service (SaaS) /
Internet-based Businesses, Technology-Enabled Services and Vertical
Software Solutions, and life sciences companies in Molecular and
Point-of-Care Diagnostics, Medical Devices and Specialty
Pharmaceuticals with capital requirements between $5 and $50
million. Safeguard participates in expansion financings, corporate
spin-outs, management buyouts, recapitalizations, industry
consolidations and early-stage financings.
http://www.safeguard.com/ Forward-Looking Statements The statements
herein regarding Clarient, Inc. contain forward-looking statements
that involve risks and uncertainty. Future events and the Company's
actual results could differ materially from the results reflected
in these forward-looking statements. Factors that might cause such
a difference include, but are not limited to: acceptance of the
KRAS offering in the marketplace and among pathologists and
patients, efficacy of the KRAS test as a predictive molecular
biomarker, the Company's ability to continue to develop and expand
its diagnostic services business, the Company's ability to expand
and maintain a successful sales and marketing organization,
unanticipated expenses or liabilities or other adverse events
affecting cash flow, uncertainty of success in identifying and
developing new diagnostic tests or novel markers, the Company's
ability to fund development of new diagnostic tests and novel
markers and the amount of resources the Company determines to apply
to novel marker development and commercialization, the Company's
ability to obtain additional financing if required on favorable
terms or at all, failure to obtain FDA clearance or approval for
particular applications, the Company's ability to compete with
other technologies and with emerging competitors in novel cancer
diagnostics and dependence on third parties for collaboration in
developing new tests, and risks detailed from time to time in the
Company's SEC reports, including quarterly reports on Form 10-Q,
reports on Form 8-K and annual reports on Form 10-K. Recent
experience with respect to laboratory services, revenues and
results of operations may not be indicative of future results for
the reasons set forth above. The company does not assume any
obligation to update any forward-looking statements or other
information contained in this document. Contact: Matt Clawson Allen
& Caron Inc (949) 474-4300 DATASOURCE: Clarient, Inc. CONTACT:
Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for
Clarient, Inc. Web site: http://www.clarientinc.com/
Copyright
Clarient, Inc. (MM) (NASDAQ:CLRT)
過去 株価チャート
から 6 2024 まで 7 2024
Clarient, Inc. (MM) (NASDAQ:CLRT)
過去 株価チャート
から 7 2023 まで 7 2024